Global Portfolio of Antimalarial Medicines

Translational
Preclinical Human volunteers Patient exploratory Product development Patient confirmatory Regulatory review Access

GSK701 GSK
NPCI11618 Mississippi
MK4815 Merck
SCR3288 Heidelberg University
Isoxazolines CalibroTropIQ
MMV370 MMV371 Janssen
MMV183 TripatIQ
MMV646 (Janssen)
S011-1793 CDRI
INE963 Novartis
P2138 Janssen
SJ733 Kentucky/Esai
ACT-451840 Idera
CDRI 9778 Icpl
MS717 Merck BSA
MMV253 Zydis Cadila
Atoguanil Icpl
MMV333 Dainabot

AQ13 Immtech
Sevuparin Mobius Therapeutics
Ganaplicidine Lumefantrine Novartis
MMV048 (UCT)
Rosiglitazone adjunct therapy Mannita, Toronto, Barcelona
Imatinib HauLee, Purtue, Turn, Sasserl and Hue

Ferroquine Artefenomel Sanofi
Ciparmin Novartis
Formidomycin Piperaquine DMG Deutsche Malaria GmbH
Methylene Blue/anoladine Heidelberg

Dihydroartemisinin-piperaquine dispersible Artesana
Co-trimoxazole ITM Antwerp
Artesinatin napthaquine Kunming Pharma Co
Artemether sub-lingual spray MRC/Safa
Artemisinin-piperaquine Araphim

Tafenoquine paediatric GSK
Sulfadoxine-pyrimethamine Universal Corporation
Sulfadoxine-pyrimethamine Swarna/Kecgan
Artemether Lumefantrine <5kg Novartis

Artemether-lumefantrine Various Manufacturers
Artemether-lumefantrine dispersible Various Manufacturers
Artesunate for Injection Various Manufacturers
Artemether for Injection Sanofi
Dihydroartemisinin-piperaquine Various Manufacturers
Tafenoquine GSK
Dihydroartemisinin-piperaquine dispersible Fasuan Pharma
Pyronaridine-Artesunate Shin Poong

Artesunate-amodiaquine Various Manufacturers
Artesunate-mellocloine G5a
Sulfadoxine-pyrimethamine-amodiaquine dispersible Various Manufacturers
Artesunate for Injection Various Manufacturers
Artesunate rectal capsules Various Manufacturers
Artesunate 60/15 US Army

Access
Approved/ERP

Footnotes: ☀ Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. ☀ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. ☀ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. ☀ paediatric formulation. ☀ via a bioequivalence study. Past partners are in brackets { }.
Footnotes: Global Portfolio

Target Product Profiles and Target Candidate Profiles


Target Product Profiles
indicated by bars at the bottom of each compound box

- 3-day cure, artemisinin-based combination therapies (TPP-1)
- Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/or resistance management (TPP-1)
- Severe malaria treatment / pre-referral intervention (TPP-1)
- Intermittent preventive treatment (TPP-1)
- Products targeting prevention of relapse for P. vivax (TPP-1)
- Prophylaxis (TPP-2)

Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio

- Asexual blood stages (TCP-1,2)
- Relapse prevention (TCP-3a)
- Transmission reduction (TCP-3b)
- Causal prophylaxis (TCP-4)

Footnote for Generic names on Global Portfolio
1. First approval: Novartis (Brand name: Coartem*). Generics by Ajanta, Cipla, Ipca, Strides Pharma, Macleods, Mylan
2. First approval: Novartis (Brand name: Coartem* Dispersible). Generics by Ajanta; Cipla; Strides Pharma; Ipca
3. Brand names: Artesun* (Fosun Pharma), Larinate* 60mg (Ipca)
4. First approval: Alfasmia (Brand name: Eurartesim*). Generic by Fosun Pharma
5. Brand name: Pyramax* tablets and granules
6. First approval fixed-dose combination: Sanofi/DNDi (Brand name: ASAQ Winthrop). Generics by Ajanta, Cipla, Fosun Pharma, Ipca, Strides Pharma, Macleods
7. Brand names: SPAQ-CO* , Supyrat* 
8. 100mg Artesunate Rectocaps
9. Artecap™
10. Brand names: Kozenis/Krintafel (Trademarks owned or licensed by GSK)
11. Brand names: ARAKODA™/KODATEF* (60 Degrees Pharmaceuticals)

Additional Symbols on Global Portfolio
- Brought into portfolio after approval; collaborations with DNDi
- No progress report in the last two years
- Global Fund Expert Review Panel (ERP) reviewed product — permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
- Paediatric formulation
- WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers
- Approved in several countries but not approved by WHO pre-qualification nor regulatory bodies who are ICH members or observers
- MMV project or MMV-supported project

September 2020